"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial comparing ibrutinib with ofatumumab for chronic lymphocytic leukaemia or small lymphocytic lymphoma
This trial compared 2 drugs called ofatumumab and ibrutinib for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It was for people whose CLL or SLL had come back or stopped responding to treatment.
If you have chronic lymphocytic leukaemia (CLL), white blood cells called
Doctors can treat CLL with chemotherapy. They may also use drugs called monoclonal antibodies such as rituximab or alemtuzumab. But CLL may stop responding to these drugs or come back after treatment.
Ofatumumab (pronounced oh-fat-oo-moo-mab) is another monoclonal antibody that doctors can use to treat CLL, when rituximab and alemtuzumab are no longer working. Ibrutinib (pronounced ib-root-in-ib) is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
This trial compared ibrutinib with ofatumumab to find out
- Which works best for CLL or SLL that has come back or is no longer responding to treatment
- More about the side effects
Summary of results
The trial team found that ibrutinib worked better than ofatumumab for people with CLL or SLL. Ibrutinib helped people to stay free of CLL or SLL for longer and increased the average time people lived.
391 people took part. Of those,
- 195 had ibrutinib tablets
- 196 had ofatumumab through a drip into a vein
An independent team, rather than the trial team, assessed the patients to see how well treatment worked. They were able to get results for 190 of the people in the ibrutinib group, and found that the CLL or SLL
- Got a bit better in 122 people (just over 64%)
- Stayed the same in 63 people (just over 33%)
- Got worse in 5 people (just under 3%)
They were able to get results for 181 people in the ofatumumab group, and found that the CLL or SLL
- Got a bit better in 8 people (just over 4%)
- Stayed the same in 153 people (just under 85%)
- Got worse 20 people (just over 11%)
Based on the above results, the doctors and the trial committee decided that people who had ofatumumab could start taking ibrutinib if their cancer got worse.
The researchers followed up the people taking part to see how many were living a year after treatment. They found that this was
- 9 out of 10 people (90%) who had ibrutinib
- About 8 out of 10 people (81%) who had ofatumumab
This analysis was done when 57 people who had been having ofatumumab changed treatment and were now taking ibrutinib.
The most common side effects of ibrutinib were diarrhoea, tiredness (fatigue), fever and feeling sick. And the most common side effects of ofatumumab were tiredness, a cough and a reaction to the drug causing fever, chills and flushing.
The researchers concluded that ibrutinib worked much better than ofatumumab for people with CLL or SLL, and it increased the average length of time that people lived.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Hilmen
NIHR Clinical Research Network: Cancer